Asia nowadays is considered definitively as the fastest-growing market, and a consolidated area for drug development. Asia not only offers the highest number of treatment-naïve patients able to participate in trials, and a steady improvement of regulations, but also offers the lowest trial cost over the world. As a part of this trend, Taiwan has developed and continues to show the world its uncapabilities for clinical trials. Penny Chen at a+ Inc. provides an overview of the potential and clinical research environment of Taiwan, considering selected critical cross-points conducting clinical trials.
 
http://jforcs.com/jcs/wp-content/uploads/2013/08/2-Clinical-Research-Environment-in-Taiwan.pdf